Can we boost enough without ritonavir?

AIDS Reader

Volumn 14, Issue 5, 2004, Pages 229-230+233

  Boffito, Marta ^a   Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

HIV AIDS; Protease inhibitor boosting; Ritonavir

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMLODIPINE; AMPRENAVIR; ASTEMIZOLE; ATAZANAVIR; ATORVASTATIN; BUSULFAN; CANNABINOID; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CLINDAMYCIN; CLOMIPRAMINE; CLONAZEPAM; CLOPIDOGREL; COCAINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DAPSONE; DELAVIRDINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; LIVER INJURY; LIVER TOXICITY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COSTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR; THERAPEUTIC EQUIVALENCY;

EID: 2442644077     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-996.
2. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16(suppl 1):S5-S37.
3. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001;2:105-113.
4. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;12:F111-F115.
5. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1626.
6. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS. 1999;13:1623-1627.
7. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695-698.
8. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
9. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641-649.
10. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29:619-624.
11. Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet. 1990;18:220-239.
12. Back D, Blaschke T, Boucher C, et al. Optimising TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. TDM Guidelines. Version 1.0. April 2003. Available at: http://www.hivpharmacology.com. Accessed April 2, 2004.
13. Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65:369-376.
14. Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50:1081-1084.
15. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit. 2000;22:122-126.
16. Brass C, Galgiani JN, Blaschke TF, et al. Related disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21:151-158.
17. Wang E, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160-165.
18. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases. Gastroenterology. 1984;86:503-513.
19. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983;74(1B):80-85.
20. Bertz R, Wong C, Carothers L, et al. Evaluation of the pharmacokinetics of multiple dose ritonavir and ketoconazole in combination [abstract]. Clin Pharmacol Ther. 1998;63:228. Abstract PIII-94.
21. Fortovase [package insert]. Hertfordshire, UK: Roche Registration Limited; 1999.
22. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gel capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Pharmacol. 2001;57:115-121.
23. Invirase [package insert]. Hertfordshire, UK: Roche Registration Limited; 1999.
24. Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2000;68:637-646.
25. Koks CH, van Heeswijk RP, Veldkamp AI, et al. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. AIDS. 2000;14:89-90.
26. Cardiello P, Kroon E, Hoetelmans R, et al. Steady-state pharmacokinetics (PK) of saquinavir (SQV) with and without two doses of itraconazole in HIV-1+ Thai patients: HIV NAT001.2 substudy. Presented at the 13th International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WeOrB545.
27. von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001;41:85-91.
28. Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:252-259.
29. Wintergerst U, Erigelhorn C, Kurowski M, et al. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS. 2000;14:1866-1868.
30. Justesen US, Klitgaard NA, Brosen K, Pedersen C. Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br J Clin Pharmacol. 2003;55:100-106.
31. Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther. 2002;72:615-626.
32. Reyataz [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2003.
33. Seminari E, Schira G, Guffanti M, et al. Pharmacokinetics (PK) of saquinavir-hard gel capsules (SQV-HGC) when combined with atazanavir (ATV) as once a day combination (1200/400) in highly experienced HIV-positive patients. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Poster 847.
34. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045 [abstract]. Antivir Ther. 2003;8(suppl 1):S212. Abstract 118.
35. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 1997;11:F117-F120.
36. Moyle G, Pozniak A, Opravil M, et al. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. J Acquir Immune Defic Syndr. 2000;23:128-137.
37. Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359. J Infect Dis. 2004;189:1176-1184.
38. Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos. 1996;24:1287-1290.
39. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet. 1994;26:91-98.
40. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45:355-359.
41. Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999;48:543-552.
42. Gorski JC, Huang SM, Pinto A, et al. Clin Pharmacol Ther. 2004,75:89-100.
43. Michalets EL. Update: clinically significant cytochrome P-450 drug interaction. Pharmacotherapy. 1998;18:84-112.
44. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
45. Mc Donnell CG, Harte S, O'Driscoll J, et al. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia. 2003;58:899-904.
46. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-370.
47. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother. 1990;26:7-29.
48. von Moltke LL, Greenblatt DJ, Schider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine and azole antifungals. J Clin Pharmacol. 1996;52:231-238.
49. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effect of liver disease. Clin Pharmacokinet. 1992;23:132-146.